PET/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)

A structured discontinuation strategy appears to provide a safe approach for long-term ICB responders, enabling earlier detection of resistance before generalized progression. A confirmatory prospective non-inferiority randomized trial within the nNGM is underway.

Authors

Institutions

Publication Details

Journal
Annals of Oncology
Published
2025-12-01
DOI
https://doi.org/10.1016/j.annonc.2025.12.011
Citations
3
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
3.14
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PET/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)

N. Reinmuth, J. Kollmeier, D. Kauffmann-Guerrero, T. Overbeck et al.
3 citations
Annals of Oncology
Cancer Immunotherapy and Biomarkers
3.14
article

PET/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)

N. Reinmuth, J. Kollmeier, D. Kauffmann-Guerrero, T. Overbeck, C. Furth, S. Braun, P. Christopoulos, P. Bischoff, M. Wermke, C. Grohé, S. Heinzen, M. Schuler, C. Kropf-Sanchen, A. Rasokat, J. Roeper, M. Reck, F. Griesinger, C. Wesseler, C. Wenzel, J. Franzen, M. Wiesweg, N. Frost, J. Kulhavy, J. Wolf, A. Rittmeyer, M. Joosten, E. Berezucki, M. Collienne, A. Bleckmann, M. Sebastian, A. Althoff
article en
3 citations

Abstract

A structured discontinuation strategy appears to provide a safe approach for long-term ICB responders, enabling earlier detection of resistance before generalized progression. A confirmatory prospective non-inferiority randomized trial within the nNGM is underway.

Annals of Oncology
Goethe University Frankfurt (DE), German Cancer Research Center (DE), Heidelberg University (DE), University Hospital Heidelberg (DE), University Hospital Regensburg (DE), Humboldt-Universität zu Berlin (DE), Helios Klinikum Emil von Behring (DE), Comprehensive Cancer Center Mainfranken (DE), University Hospital Münster (DE), National Center for Tumor Diseases (DE), Universitätsmedizin Göttingen (DE), Essen University Hospital (DE), Pius Hospital Oldenburg (DE), German Center for Lung Research (DE), University Hospital Frankfurt (DE), Asklepios Klinikum Harburg (DE), Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE), Sana Klinikum Offenbach (DE), Evangelische Lungenklinik Berlin (DE), University Hospital Cologne (DE), University Medical Centre Mannheim (DE), Frankfurt Cancer Institute (DE), West German Heart and Vascular Center Essen (DE), University Hospital Carl Gustav Carus (DE), University of Göttingen (DE), Ludwig-Maximilians-Universität München (DE)
Good health and well-being
Openalex Percentile: Top 7%
Cancer Immunotherapy and Biomarkers
3.14
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.